期刊文献+

高尿酸血症对无保护左主干冠心病患者长期预后的影响 被引量:1

Influence of hyperuricacidemia on long-term prognosis in patients with coronary heart disease of unprotected left main coronary artery lesions
下载PDF
导出
摘要 目的研究血尿酸水平对无保护左主干病变的冠状动脉粥样硬化性心脏病(冠心病)患者预后的影响。方法入选2011年1月至2016年7月行经皮冠状动脉介入术(PCI)或冠状动脉旁路移植术(CABG)治疗的无保护左主干病变的冠心病患者881例,记录患者术前血尿酸基线水平,根据血尿酸水平分为高尿酸组(n=196)和正常尿酸组(n=685)。从手术结束后第1 d开始随访,平均随访时间5.1年。采用独立样本t检验或χ^(2)检验进行两组间基线资料的对比,采用单因素和多因素COX比例风险模型预测心血管不良联合终点事件(MACCE),包括全因死亡、非致命性心肌梗死、卒中及再次血运重建等发生的危险因素及保护因素,采用Kaplan-Meier法比较两组患者MACCE事件的差异。结果与正常尿酸组相比,高尿酸组患者的高脂血症、高血压病、脑血管病和血肌酐水平明显增高(P<0.05)。COX风险比例模型显示,校正前高尿酸组患者的MACCE发生率升高(HR=1.547,95%CI:1.19~2.01,P=0.001),多因素校正后显示高尿酸、高脂血症是MACCE发生率的独立危险预测因素,危险比分别为(HR=1.387,95%CI:1.06~1.82,P=0.017)和(HR=1.315,95%CI:1.03~1.68,P=0.027),而左室射血分数是MACCE发生率的独立保护因素(HR=0.983,95%CI:0.97~0.99,P=0.002)。Kaplan-Meier曲线显示高尿酸组患者累积事件包括全因死亡、非致死性心肌梗死、卒中及再次血运重建的联合终点发生率要高于正常尿酸组患者(log-rankχ^(2)=10.78,P=0.001)。结论高血尿酸水平与冠心病无保护左主干病变患者的不良预后具有一定相关性,对于冠心病无保护左主干病变患者,应该更严格的控制其尿酸水平。 Objective To study the influence of blood uric acid(BUA)on prognosis in patients with coronary heart disease of unprotected left main coronary artery lesions(CHD-ULM).Methods The patients(n=881)with CHD-ULM undergone percutaneous coronary intervention(PCI)or coronary artery bypass grafting(CABG)were chosen from Jan.2011 to July 2016,and baseline BUA level were recorded before the operation.All patients were divided into high BUA group(n=196)and normal BUA group(n=685).The patients were followed up on the first day after the operation,and mean follow-up period was 5.1 y.The baseline materials were compared between 2 groups by using independent-sample t test orχ^(2) test.The risk factors and protective factors of major adverse cardiovascular and cerebrovascular events(MACCE,including all-cause mortality,non-fatal myocardial infarction,stroke and re-revascularization)were predicted by using single-factor and multi-factor COX proportional hazard model.The difference in MACCE was compared between 2 groups by using Kaplan-Meier method.Results The percentages of cases of hyperlipidemia,hypertension and cerebral artery disease and level of serum creatinine(SCr)increased significantly in high BUA group compared with normal BUA group(P<0.05).The results of COX risk proportion model analysis showed that incidence rate of MACCE increased in high BUA group before correcting(HR=1.547,95%CI:1.19~2.01,P=0.001).The results of multi-factor correcting showed that hyperuricacidemia(HR=1.387,95%CI:1.06-1.82,P=0.017)and hyperlipidemia(HR=1.315,95%CI:1.03~1.68,P=0.027)were independent risk predictive factors of MACCE incidence,while left ventricular ejection fraction(LVEF)was a dependent protective factor of MACCE incidence(HR=0.983,95%CI:0.97~0.99,P=0.002).The results of Kaplan-Meier curve analysis showed that MACCE incidence rates,including all-cause mortality,non-fatal myocardial infarction,stroke and re-revascularization were higher in high BUA group than those in normal BUA group(log-rankχ^(2)=10.78,P=0.001).Conclusion There is a correlation between high BUA and poor prognosis in patients with CHD-ULM,and BUA level should be more strictly controlled in the patients.
作者 闫贤良 林运 高玉龙 陶英 张京梅 李志忠 Yan Xianliang;Lin Yun;Gao Yulong;Tao Ying;Zhang Jingmei;Li Zhizhong(Department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China;不详)
出处 《中国循证心血管医学杂志》 2022年第3期326-329,共4页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 冠状动脉疾病 无保护左主干病变 尿酸 预后 Coronary artery lesions Coronary heart disease of unprotected left main coronary artery lesions Blood uric acid Prognosis
  • 相关文献

参考文献3

二级参考文献21

  • 1Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555.
  • 2Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651.
  • 3Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210.
  • 4Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13.
  • 5Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972.
  • 6Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932.
  • 7Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx.
  • 8Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243.
  • 9Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Cell Cardiol,2007,50 : 1742-1751.
  • 10Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 2011,123:2736-2747.

共引文献448

同被引文献16

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部